A study about the anticancer agent-related gene change in the human lung cancer orthotopic implantation model

人肺癌原位种植模型中抗癌药物相关基因变化的研究

• 批准号: 18591552
• 负责人: MIYOSHI Takanori
• 金额: $ 2.53万
• 依托单位: Department of Clinical Research, National Hospital Organization Tokushima National Hospital (2007)The University of Tokushima (2006)
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18591552/
• 关键词: esophageal cancer; thyroid anaplastic carcinoma; lung cancer; orthotopic implantation model; lymph node metastasis; metastasis related gene; anti cancer agent related gene; TaqMan Low Density Array

The human lung cancer orthotopic implantation model uses an SCID mouse and forms the primary tumor and succeeds in making the mediastinal lymph node metastasis model. It is the rare for the cancer model. Therefore, using ACT-1 cells (anaplastic carcinoma of thyroid) and YES-3 cells (esophageal cancer), we made the human cancer cell models with SCID mouse. The method fixes the SCID mouse in face up position under the anesthesia. We shut stomach after adding about 1.5cm horizontal incision to an epigastric region in the case of the gullet and perform an operation and expose the esophagus, and having injected cell suspension 10 μ ml which we prepared beforehand in the esophageal muscular layer with 30G needle. We shut wound after adding horizontal incision to a cervix in the case of the thyroid gland and expose the trachea and confirm the thyroid gland, and having injected cell suspension 10 μ ml in the thyroid gland with 30G needle. Four weeks later, the model formed micro-metastases in … More six weeks, and formed macro-metastases in eight weeks. In addition, the thyroid carcinoma did neoplasia in the thyroid gland in injection six weeks and understood that caused mediastinum lymph node metastasis in eight weeks. Because it was able to reproduce lymph node metastasis of the cancer of the human esophageal cancer in the mouse, each thyroid carcinoma, there was it of contribution preparations to the magazine of the cancer connection now because I perform these supplementary examinations, and it was possible for a course in correct time in progress to make the metastasis from neoplasia.In addition, we performed the anticancer agent dosage, and it was the examination of the anticancer agent in the tumor-related gene change, but we decided to perform it in a model under the skin before aforementioned place transplant model, and making of, 5-FU and CDDP administered a tumor to the SCID mouse subcutaneous about a YES-3 cell between things of resistant acquisition during the dosage. We gathered each tumor organization at the time of effect expression the anticancer agent dosage ago at resistant acquisition time. For genetic norrowing, I searched it in DNA array. It was suggested that PI3K/Akt signaling pathway was related to resistant acquisition. I perform the anticancer agent dosage with the aforementioned place transplant model mentioned above and am going to perform a study about the anticancer agent connection gene change in the orthotopic implantation model. Less

人肺癌原位移植模型采用SCID小鼠，形成原发肿瘤，成功制作纵隔淋巴结转移模型。这是罕见的癌症模型。因此，使用ACT-1细胞（甲状腺未分化癌）和YES-3细胞（食管癌），我们用SCID小鼠制作了人癌细胞模型。该方法在麻醉下将SCID小鼠固定在面朝上的位置。我们在食道的情况下，在上腹部增加约1.5cm的水平切口后关闭胃，并进行手术，暴露食管，并用30 G针头将预先制备的细胞悬液10 μ ml注入食管肌层。在甲状腺病例中，我们在子宫颈增加水平切口后关闭伤口，暴露气管并确认甲状腺，并用30 G针头在甲状腺中注射细胞悬液10 μ ml。4周后，该模型形成微转移， ...更多信息 6周后形成大转移灶。另外，甲状腺癌在注射后6周内发生甲状腺内瘤变，8周后发生纵隔淋巴结转移。因为能够在小鼠中再现人食管癌的癌的淋巴结转移，每个甲状腺癌，因为我进行这些补充检查，现在有对癌症联系的杂志的贡献准备，并且有可能在正确的时间进行一个过程，以使肿瘤转移。此外，我们进行了抗癌剂剂量，并且是肿瘤相关基因变化中抗癌剂的检查，但是我们决定在上述位置移植模型之前在皮下模型中进行，并且在给药期间，将5-FU和CDDP给药到关于YES-3细胞的皮下肿瘤的SCID小鼠，在耐药获得的事情之间。我们收集了每个肿瘤组织在效果表达时的抗癌药物剂量前在耐药获得时的情况。我在DNA阵列中搜索了它的基因序列。提示PI 3 K/Akt信号通路与抗性获得有关。本人使用上述的原位移植模型进行抗癌剂的给药，并将在原位移植模型中进行关于抗癌剂连接基因变化的研究。少

项目成果

食道癌生検組織における5-FU代謝酵素の発現とDocetaxel併用化学療法との関連性

食管癌活检组织中5-FU代谢酶的表达及其与多西紫杉醇联合化疗的关系

• 发表时间: 2007
• 作者: 藤澤武彦;渋谷 潔(内視鏡的レーザー治療 分担執筆);Okubo Chigusa;穴見洋一;Anami Yoichi;野口雅之;穴見洋一;穴見洋一;穴見洋一;野口雅之;穴見洋一;穴見洋一;穴見洋一;森下由紀雄;吉田 卓弘
• 通讯作者: 吉田 卓弘

The expression of the 5-FU metabolism enzyme in the esophageal cancer biopsy specimens and the relationship with the Docetaxel combination chemotherapy

食管癌活检标本中5-FU代谢酶的表达及其与多西紫杉醇联合化疗的关系

• 发表时间: 2007
• 作者: 藤澤武彦;渋谷 潔(内視鏡的レーザー治療 分担執筆);Okubo Chigusa;穴見洋一;Anami Yoichi;野口雅之;穴見洋一;穴見洋一;穴見洋一;野口雅之;穴見洋一;穴見洋一;穴見洋一;森下由紀雄;吉田 卓弘;Takahiro Yoshida
• 通讯作者: Takahiro Yoshida

食道癌生検組織における5-FU代謝酵素の発現とDocetaxel併用化学療法と関連性

食管癌活检组织中5-FU代谢酶的表达及其与多西紫杉醇联合化疗的关系

• 发表时间: 2007
• 作者: 藤澤武彦;渋谷 潔(内視鏡的レーザー治療 分担執筆);Okubo Chigusa;穴見洋一;Anami Yoichi;野口雅之;穴見洋一;穴見洋一;穴見洋一;野口雅之;穴見洋一;穴見洋一;穴見洋一;森下由紀雄;吉田 卓弘;Takahiro Yoshida;吉田 卓弘
• 通讯作者: 吉田 卓弘